Few employers are planning to eliminate their health benefits in 2015, but they are still looking to make noticeable changes, according to a report from the Employee Benefit Research Institute.
Few employers are planning to eliminate their health benefits in 2015, but they are still looking to make noticeable changes, according to a report from the Employee Benefit Research Institute (EBRI).
The report uses findings from the SHRM/EBRI 2014 Health Benefits Survey, which found just 1% of plan sponsors expect to eliminate health benefits in 2015, but a large number of employers will continue to introduce wellness rewards and penalties.
“We are in the middle of open enrollment season, so we figured people would be interested to know what health plan sponsors are thinking,” Paul Fronstin, director of EBRI’s Health Research and Education Program, and author of the report, said in a statement. “We found that very few employers plan to make major changes—at least for now—and most seem to be moving toward adoption of wellness programs.”
The most common change employers will make to healthcare plans in 2015 is adding wellness rewards or penalties (26.3%), followed by requiring spouses to get coverage through their own employer (7.9%), institute spousal surcharge (6.7%), and create tiered networks (3.6%). Just 1% plans to eliminate coverage entirely and 1.3% plans to eliminate coverage for part-time workers.
Other plan design options garnering less interest right now were private health insurance exchanges (3.2%), value-based insurance design (2.6%), or reference pricing (0.6%).
Changes to healthcare plans are being led by large companies with 750 or more full-time employees. More than a third (34.6%) of large employers will add wellness rewards or penalties, for instance.
According to the EBRI report, the increasing interest in wellness programs may be a result of both the Affordable Care Act’s financial incentives and the 2018 excise tax on high-cost health plans. As of now, 15% of plan sponsored expect at least one of their plans will trigger the excise tax.
“Ultimately, concerns about triggering the excise tax on high-cost health plans may result in accelerated adoption of tiered networks, private health insurance exchanges, value-based insurance design, and reference pricing,” the report concludes.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More